Prasugrel

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia, Sickle Cell

Conditions

Anemia, Sickle Cell

Trial Timeline

Jul 1, 2010 → Jan 1, 2011

About Prasugrel

Prasugrel is a phase 1 stage product being developed by Daiichi Sankyo for Anemia, Sickle Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT01178099. Target conditions include Anemia, Sickle Cell.

What happened to similar drugs?

20 of 20 similar drugs in Anemia, Sickle Cell were approved

Approved (20) Terminated (5) Active (0)

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03672097ApprovedCompleted
NCT01476696Phase 2Completed
NCT01178099Phase 1Completed

Competing Products

20 competing products in Anemia, Sickle Cell

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40